Inocras inc.

Inocras is a biotechnology company specializing in whole genome sequencing (WGS) and AI-powered genomic interpretation for precision health applications. The platform serves patients, healthcare providers, and researchers, with a focus on oncology and rare disease diagnostics in a CAP-accredited and CLIA-certified laboratory setting. Product Breakdown Inocras offers a suite of genomic services tailored to different user groups: CancerVision: A tumor-informed, paired somatic-germline whole-genome sequencing test for solid tumor cancers. It includes target-enhanced WGS (~40-500× depth), detecting SNVs, indels, structural variants, CNVs, with analytic features such as TMB, MSI, HRD, and clinical trial matching support. Results delivered within a two-week turnaround time and backed by genetic counseling. RareVision: A comprehensive WGS test for rare disease diagnosis. Covers over 5,000 rare disease-associated genes, analyzes both coding and non-coding regions, and includes genetic counseling support. Offers detailed variant interpretation aligned with ACMG/ClinGen guidelines, delivered in approximately two weeks. MRDVision: An ultra-sensitive (1 ppm detection) whole-genome, tumor-informed circulating tumor DNA (ctDNA) assay for minimal residual disease monitoring. It requires no targeted panels and is intended for high-precision oncology applications. Research Services: End-to-end CLIA/CAP-certified sequencing services including whole-genome sequencing, bioinformatics, data curation, and advisory support for research use, designed for biopharmaceutical, academic, and biobank clients, with typical two-week turnaround.